NOV 02, 2016 12:00 PM PDT

Immunoassays and Pain Management Drug Testing

C.E. CREDITS: P.A.C.E. CE | Florida CE
Speakers
  • Director; Siemens Healthineers
    Biography
      Nihmat Morjana, Ph.D., M.Sc. is a Director at Siemens Healthineers. Dr. Morjana received his Ph.D. in Biochemistry, from Queen's University working on the structure/mechanism and drug interaction of Aldo-Keto Reductases. Following his post-doctoral training at Baylor College of Medicine, he joined Baxter/Dade International/Dade Behring/Siemens. He led projects on the development and commercialization of drugs of abuse, pain management and immunosuppressant immunoassays. Dr. Morjana has 24 years of experience in the diagnostic industry. His current work focus includes immunoassay and application development on multiple-instruments. He is a member of ASBMB, SOFT and AACC and has published peer reviewed papers and abstracts and an inventor on patents. He is on the Editorial Board of Biotechnology and applied Biochemistry and served on the Editorial board of the Internet Journal of Genomics and Proteomics.

    Abstract:

    In the past several years, there has been an increase in drug testing associated with chronic pain. Immunoassays are the most common method for initial screening which can test for a specific drug, metabolite, or a class of drugs.  The drug tests are used routinely in the workplace drug testing and periodic testing for drug compliance.  Commercially available immunoassays vary in their features, specificities, and screening thresholds.  Therefore, the results should be looked at with understanding of the immunoassay used in the testing and drug metabolism.  Immunoassays, which are designed for detection of the abuse of drugs, may be suitable for pain management testing.   Immunoassay low cutoff levels may provide laboratories with more sensitive methods for drug monitoring and in identifying abuse and misuse of prescription drugs.  This presentation will discuss immunoassay features, commercial drug tests for opioids/other drugs, and their suitability for pain management testing.
     


    Show Resources
    You May Also Like
    MAY 22, 2018 08:00 AM PDT
    C.E. CREDITS
    MAY 22, 2018 08:00 AM PDT
    DATE: May 22, 2018TIME: 08:00AM PDT The nuclear receptors pregnane X receptor (PXR) and constitutive androstane receptor (CAR) are closely related transcription factors that...
    MAY 03, 2018 11:00 AM PDT
    MAY 03, 2018 11:00 AM PDT
    DATE: May 3, 2018TIME: 11:00AM PDT, 2:00PM EDTWhile stress is one of the leading causes of neuropsychiatric disorders, the molecular underpinnings of how stress induces alterations in b...
    MAY 24, 2018 09:30 AM PDT
    C.E. CREDITS
    MAY 24, 2018 09:30 AM PDT
    DATE: May 24, 2018 TIME: 9:30PM PDT The current gold standard in in vitro pre-clinical cancer treatment screening remain cell lines,...
    JUN 26, 2018 06:00 AM PDT
    C.E. CREDITS
    JUN 26, 2018 06:00 AM PDT
    Date: June 26, 2018Time: 6:00 a.m. PDT, 9:00 a.m. EDT, 1500 CEST Today’s hematology analyzers employ various methods for enumerating platelets. These methods include: e...
    APR 27, 2018 10:00 AM PDT
    C.E. CREDITS
    APR 27, 2018 10:00 AM PDT
    DATE: April 27, 2018TIME: 10:00am PST, 1:00pm ESTGlioblastoma (GBM) and Medulloblastoma (MB) are the most common adult and paediatric brain tumours, both of which can have devastating c...
    JUN 20, 2018 10:00 AM EDT
    C.E. CREDITS
    JUN 20, 2018 10:00 AM EDT
    DATE: June 20, 2018TIME: 07:00AM PDT, 10:00AM EDTIntroducing GE’s New Lyo-StableTM service. Sepsis is one of the top challenges facing hospitals in terms of clinical outcomes...
    Loading Comments...